STAT3 and cancer: Accordingly, cancer cells engineered to overexpress STAT3C remain largely unresponsive to the inhibitory effects of silibinin on key transcriptional and phenotypic targets of STAT3 (e.g., c-myc expression and metabolic reprogramming) [88,92].